SCHEMBL3428148

SCHEMBL3428148

NC(=O)c1ccc(NC(=O)c2nn(Cc3ccc(C(=O)N4CCOCC4)cc3)c3ccccc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.55
PTGER4 P35408 4/20 0.48
POLB P06746 1/20 0.46
KDM4E B2RXH2 1/20 0.46
NAMPT P43490 1/20 0.46
ELANE P08246 2/20 0.46
HIF1A Q16665 1/20 0.45
EPAS1 Q99814 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HPGD P15428 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428309 0.89 PTGER4 (0.59) FLT3PTGER4KDM4EHIF1AEPAS1
SCHEMBL3428968 0.89 FLT3 (0.52) FLT3PTGER4KDM4EELANETDP1
SCHEMBL3428482 0.87 PTGER4 (0.61) FLT3PTGER4NAMPTSMN1; SMN2ABL1
SCHEMBL3430447 0.86 KMT2A (0.54) NPC1ALDH1A1LMNAMAPTHTT
SCHEMBL3431403 0.86 RAB9A (0.56) FLT3POLBKDM4EELANENPC1
SCHEMBL3760296 0.85 NPC1 (0.57) FLT3PTGER4POLBELANEHPGD
SCHEMBL3429976 0.83 FLT3 (0.47) FLT3PTGER4POLBNAMPTELANE
SCHEMBL3429688 0.83 MAPK1 (0.48) FLT3PTGER4POLBNAMPTHPGD
SCHEMBL3428165 0.83 PTGER4 (0.54) PTGER4KDM4EHIF1AHPGDALDH1A1
SCHEMBL3403474 0.81 PTGER4 (0.50) PTGER4ELANEHPGDSMN1; SMN2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 FLT3 4692/4885PTGER4 3500/4885POLB 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.